Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 13580
Country/Region: Zambia
Year: 2015
Main Partner: Centre for Infectious Diseases Research in Zambia
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $23,419,169 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,944,756
Care: TB/HIV (HVTB) $2,325,000
Care: Pediatric Care and Support (PDCS) $881,796
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $90,000
Health Systems Strengthening (OHSS) $81,442
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $1,025,697
Testing: HIV Testing and Counseling (HVCT) $770,478
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $3,600,000
Treatment: Adult Treatment (HTXS) $10,700,000
Treatment: Pediatric Treatment (PDTX) $2,000,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Age/sex: <1 Female 2016 138
CARE_CURR Age/sex: <1 Female 2016 6
CARE_CURR Age/sex: <1 Male 2016 8
CARE_CURR Age/sex: <1 Male 2016 110
CARE_CURR Age/sex: 1-4 Female 2016 1,730
CARE_CURR Age/sex: 1-4 Female 2016 121
CARE_CURR Age/sex: 1-4 Male 2016 114
CARE_CURR Age/sex: 1-4 Male 2016 1,596
CARE_CURR Age/sex: 10-14 Female 2016 2,624
CARE_CURR Age/sex: 10-14 Female 2016 186
CARE_CURR Age/sex: 10-14 Male 2016 2,641
CARE_CURR Age/sex: 10-14 Male 2016 188
CARE_CURR Age/sex: 15-19 Female 2016 3,608
CARE_CURR Age/sex: 15-19 Female 2016 238
CARE_CURR Age/sex: 15-19 Male 2016 2,084
CARE_CURR Age/sex: 15-19 Male 2016 161
CARE_CURR Age/sex: 20-24 Female 2016 16,075
CARE_CURR Age/sex: 20-24 Female 2016 884
CARE_CURR Age/sex: 20-24 Male 2016 6,966
CARE_CURR Age/sex: 20-24 Male 2016 486
CARE_CURR Age/sex: 25-49 Female 2016 92,972
CARE_CURR Age/sex: 25-49 Female 2016 5,757
CARE_CURR Age/sex: 25-49 Male 2016 66,016
CARE_CURR Age/sex: 25-49 Male 2016 3,848
CARE_CURR Age/sex: 5-9 Female 2016 2,891
CARE_CURR Age/sex: 5-9 Female 2016 207
CARE_CURR Age/sex: 5-9 Male 2016 197
CARE_CURR Age/sex: 5-9 Male 2016 2,771
CARE_CURR Age/sex: 50+ Female 2016 30,482
CARE_CURR Age/sex: 50+ Female 2016 1,851
CARE_CURR Age/sex: 50+ Male 2016 16,668
CARE_CURR Age/sex: 50+ Male 2016 1,227
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 15,479
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 249,372
CARE_CURR Sum of Age/Sex disaggregates 2016 249,372
CARE_CURR Sum of Age/Sex disaggregates 2016 15,479
CARE_NEW Age/sex: <1 Female 2016 67
CARE_NEW Age/sex: <1 Male 2016 53
CARE_NEW Age/sex: 1-4 Female 2016 507
CARE_NEW Age/sex: 1-4 Male 2016 492
CARE_NEW Age/sex: 10-14 Female 2016 362
CARE_NEW Age/sex: 10-14 Male 2016 200
CARE_NEW Age/sex: 15-19 Female 2016 1,100
CARE_NEW Age/sex: 15-19 Male 2016 324
CARE_NEW Age/sex: 20-24 Female 2016 4,558
CARE_NEW Age/sex: 20-24 Male 2016 1,947
CARE_NEW Age/sex: 25-49 Female 2016 17,912
CARE_NEW Age/sex: 25-49 Male 2016 10,116
CARE_NEW Age/sex: 5-9 Female 2016 350
CARE_NEW Age/sex: 5-9 Male 2016 295
CARE_NEW Age/sex: 50+ Female 2016 3,905
CARE_NEW Age/sex: 50+ Male 2016 1,964
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 44,152
CARE_NEW Sum of Age/sex disaggregates 2016 44,152
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 2,090
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 2,859
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 29,990
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 13,990
HTS_TST By Test Result: Negative 2016 45,060
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 48,929
HTS_TST Sum of Aggregated Age/Sex <15 2016 4,949
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 43,980
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 48,929
HTS_TST Sum of Test Result disaggregates 2016 48,929
HTS_TST_POS By Test Result: Positive 2016 3,869
LAB_CAP By clinical laboratories 2016 15
LAB_CAP By Point-of-care testing sites 2016 10
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 21
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2016 3
LAB_PT CD4: Number of laboratories that participate in this PT program 2016 3
LAB_PT CD4: Number of laboratories that perform this testing 2016 11
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2016 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2016 18
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2016 25
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 9,514
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 8,984
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 896
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 774
PMTCT_ARV Sum of New and Current disaggregates 2016 1,670
PMTCT_ARV Sum of Regimen Type disaggregates 2016 4,222
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 3,827
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 5,594
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 9,461
PMTCT_EID Sum of Infant Age disaggregates 2016 9,421
PMTCT_STAT By: Known positives at entry 2016 4,187
PMTCT_STAT By: Known positives at entry 2016 6,451
PMTCT_STAT By: Number of new positives identified 2016 4,407
PMTCT_STAT By: Number of new positives identified 2016 6,789
PMTCT_STAT Number of new ANC and L&D clients 2016 69,715
PMTCT_STAT Number of new ANC and L&D clients 2016 103,312
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 65,931
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 97,475
PMTCT_STAT Sum of Positives Status disaggregates 2016 8,594
PMTCT_STAT Sum of Positives Status disaggregates 2016 13,240
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 688
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 688
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 15,479
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 249,372
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 18,923
TX_CURR Age/Sex: <1 Female 2016 25
TX_CURR Age/Sex: <1 Female 2016 363
TX_CURR Age/Sex: <1 Male 2016 20
TX_CURR Age/Sex: <1 Male 2016 355
TX_CURR Age/Sex: 1-4 Female 2016 163
TX_CURR Age/Sex: 1-4 Female 2016 2,191
TX_CURR Age/Sex: 1-4 Male 2016 161
TX_CURR Age/Sex: 1-4 Male 2016 2,161
TX_CURR Age/Sex: 5-14 Female 2016 476
TX_CURR Age/Sex: 5-14 Female 2016 11,890
TX_CURR Age/Sex: 5-14 Male 2016 466
TX_CURR Age/Sex: 5-14 Male 2016 5,046
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 10,689
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 172,204
TX_CURR Sum of age/sex disaggregates 2016 172,204
TX_CURR Sum of Age/Sex disaggregations 2016 10,683
TX_NEW By Age/Sex: <1 Female 2016 81
TX_NEW By Age/Sex: <1 Male 2016 63
TX_NEW By Age/Sex: 1-4 Female 2016 344
TX_NEW By Age/Sex: 1-4 Male 2016 347
TX_NEW By Age/Sex: 10-14 Female 2016 437
TX_NEW By Age/Sex: 10-14 Male 2016 248
TX_NEW By Age/Sex: 15-19 Female 2016 1,151
TX_NEW By Age/Sex: 15-19 Male 2016 216
TX_NEW By Age/Sex: 20-24 Female 2016 4,004
TX_NEW By Age/Sex: 20-24 Male 2016 1,218
TX_NEW By Age/Sex: 25-49 Female 2016 12,223
TX_NEW By Age/Sex: 25-49 Male 2016 10,702
TX_NEW By Age/Sex: 5-9 Female 2016 374
TX_NEW By Age/Sex: 5-9 Male 2016 260
TX_NEW By Age/Sex: 50+ Female 2016 3,481
TX_NEW By Age/Sex: 50+ Male 2016 1,436
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 36,588
TX_NEW Pregnancy status 2016 10,555
TX_NEW Sum of Age/Sex disaggregates 2016 36,585
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 28,474
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 31,561
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2016 188
VMMC_CIRC By Age: 1-9 2016 1,942
VMMC_CIRC By Age: 10-14 2016 5,328
VMMC_CIRC By Age: 15-19 2016 4,813
VMMC_CIRC By Age: 20-24 2016 2,753
VMMC_CIRC By Age: 50+ 2016 820
VMMC_CIRC By circumcision technique: Surgical VMMC 2016 16,621
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2016 6,960
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2016 11,801
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2016 8,234
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2016 9,734
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2016 792
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 18,761
VMMC_CIRC Sum of age disaggregates 2016 15,709